| Type of Material: | Thesis |
| Title: | Purification of Protein Charge Variants and Determination of their Potency |
| Researcher: | Kumar, Tarun |
| Guide: | Seshadri, Sriram |
| Department: | Institute of Science |
| Publisher: | Nirma University, Ahmedabad |
| Place: | Ahmedabad |
| Year: | 2024 |
| Language: | English |
| Subject: | Chromatography | Life Sciences | Microbiology | Monoclonal | Microbiology | Life Science |
| Dissertation/Thesis Note: | PhD; Institute of Science, Nirma University, Ahmedabad, Ahmedabad; 2024 |
| Fulltext: | Shodhganga |
| 000 | 00000ntm a2200000ua 4500 | |
| 001 | 456539 | |
| 003 | IN-AhILN | |
| 005 | 2024-10-10 17:32:18 | |
| 008 | __ | 241010t2024||||ii#||||g|m||||||||||eng|| |
| 035 | __ | |a(IN-AhILN)th_456539 |
| 040 | __ | |aNIRU_382481|dIN-AhILN |
| 041 | __ | |aeng |
| 100 | __ | |aKumar, Tarun|eResearcher |
| 110 | __ | |aInstitute of Science|bNirma University, Ahmedabad|dAhmedabad|ein|0U-0146 |
| 245 | __ | |aPurification of Protein Charge Variants and Determination of their Potency |
| 260 | __ | |aAhmedabad|bNirma University, Ahmedabad|c2024 |
| 300 | __ | |dDVD |
| 502 | __ | |cInstitute of Science, Nirma University, Ahmedabad, Ahmedabad|d2024|bPhD |
| 518 | __ | |d2024|oDate of Award |
| 518 | __ | |oDate of Registration|d2020 |
| 520 | __ | |aMonoclonal antibodies (mAbs) related biological drugs are fastest growing in therapeutic industries across the globe. mAbs were in top best-selling categories of antibody related therapies in 2015. The interest towards mAbs biosimilar development is increasing day by day as there are many patents filed by innovators are supposed to be expire soon. Biosimilars are highly complex and similar biological drugs are developed with different manufacturing processes which are not similar to originator manufacturing process. Due to this, biosimilar product inherently has quality differences in comparison to innovator molecule which may be related to size, charge and glycosylation. Despite these differences they are supposed to demonstrate similar behaviour in safety and efficacy profile to the reference product and these differences should not be clinically meaningful. Charge variants are one of the critical quality attributes and sources of heterogeneity. Omalizumab (Xolair) is a humanized monoclonal antibody deriv |
| 650 | __ | |aMicrobiology|2UGC |
| 650 | __ | |aLife Science|2AIU |
| 653 | __ | |aChromatography |
| 653 | __ | |aLife Sciences |
| 653 | __ | |aMicrobiology |
| 653 | __ | |aMonoclonal |
| 700 | __ | |eGuide|aSeshadri, Sriram |
| 856 | __ | |uhttp://shodhganga.inflibnet.ac.in/handle/10603/584084|yShodhganga |
| 905 | __ | |afromsg |
User Feedback Comes Under This section.